Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Research Protocols On DTC Brief Summary Info To Be Finalized In Fall

Executive Summary

FDA expects to finalize internal protocols this fall for agency-conducted studies on the brief summary information in direct-to-consumer ads

You may also be interested in...



AstraZeneca Questions Value Of DTC Ads, But Is Still Launching New TV Spots

AstraZeneca will soon have both experimental and marketplace data to help refine its new policies on direct-to-consumer advertising

AstraZeneca Questions Value Of DTC Ads, But Is Still Launching New TV Spots

AstraZeneca will soon have both experimental and marketplace data to help refine its new policies on direct-to-consumer advertising

FDA DTC Study Should Use Real Ads, Be More Conversational – AstraZeneca

AstraZeneca is asking FDA to incorporate a more qualitative approach in the initial phase of its planned evaluation of the "brief summary" section of direct-to-consumer print advertising

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS044677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel